Eiger BioPharmaceuticals Unveils Results of Preclinical Studies

Eiger BioPharmaceuticals said Wednesday it has published in the Science Translational Medicine journal results of extensive preclinical studies of ubenimex, in which modulation of the inflammatory mediator, leukotriene B4 (LTB4), improved experimental lymphedema. Targeted reduction of LTB4 with ubenimex reversed edema, improved lymphatic function and restored lymphatic architecture in experimental models of lymphedema, the company said in a press release.

Based on these findings, Eiger is conducting ULTRA, a multi-center, phase 2 clinical study of ubenimex in secondary lymphedema, currently enrolling at multiple sites in the U.S. and Australia. The technology was invented by Stanley Rockson, MD, Professor of Cardiovascular Medicine at Stanford University, which Eiger exclusively licensed in 2015.
Lymphedema is a state of vascular functional insufficiency in which decreased lymphatic clearance of interstitial fluid leads to edema formation, and progressive, debilitating architectural alterations of the skin and supporting tissues. It typically manifests itself in an arm or leg, but can affect other parts of the body. Lymphedema often causes long-term physical, psychological, and social problems for patients and significantly impacts quality of life. There is no approved pharmacologic therapy.

By Stephen Holmes